PHARMACEUTICAL 2012

Jazz Pharmaceuticals plc
Rank 15 of 196



TOP RATED 2012

RealRate

PHARMACEUTICAL 2012

Jazz Pharmaceuticals

Jazz Pharmaceuticals plc
Rank 15 of 196

The relative strengths and weaknesses of Jazz Pharmaceuticals plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Jazz Pharmaceuticals plc compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 120% points.The greatest weakness of Jazz Pharmaceuticals plc is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 11% points.

The company's Economic Capital Ratio, given in the ranking table, is 415%, being 181% points above the market average of 234%.

Input Variable	Value in 1000 USD
Assets, Current	199,131
Cost of Goods Sold	0
Intangible Assets	52,798
Liabilities, Current	52,870
Liabilities, Non-Current	0
Other Assets	87
Other Compr. Net Income	0
Other Expenses	23,065
Other Liabilities	0
Other Net Income	-1,172
Other Revenues	272,277
Property and Equipment	1,557
Research and Development	14,120
Selling, General and Administrative Expense	108,936

Output Variable	Value in 1000 USD
Assets	253,573
Liabilities	52,870
Expenses	146,121
Revenues	272,277
Stockholders Equity	200,703
Net Income	124,984
Comprehensive Net Income	124,984
BaseVar	363,006
ECR before LimitedLiability	367%
Economic Capital Ratio	415%